ERBB2 and urinary bladder cancer: Particularly, in bladder cancer, the presence/overexpression of GnT-III/IV, Lex, Ley, SLex, STn, ST6GalNAc.I, T-antigen, ST3Gal.I, HER2, EpCAM, galectin-1, galectin-3, CD44, CD44v9, MUC1, MUC4, ITGA6, ITGAV, neuropilin-1, neuropilin-2, versican, decorin, biglycan, endocan, HYAL1, hyaluronic acid synthase 1, RHAAM, glucosylceramide synthase, and PIG-U was associated with more aggressive phenotypes and/or poor prognosis [20, 30, 46, 50, 54, 64-67, 76, 82, 86, 87, 96, 97, 101-103, 120, 121, 124, 125, 129, 133, 139, 165-168, 171, 172, 176, 177, 179-181, 198, 208, 209].